OPKO Health, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
OPKO Health, Inc. (OPK) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.64 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- OPKO Health, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $1.64.
- OPKO Health, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- OPKO Health, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $2.12, a 9.40% decline from fiscal 2022.
- OPKO Health, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $2.34, a 3.70% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $1.64 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 |
| 2023-12-31 | $2.12 10-K · filed 2024-03-01 |
| 2022-12-31 | $2.34 10-K · filed 2023-02-27 |
| 2021-12-31 | $2.43 10-K · filed 2022-03-01 |
| 2020-12-31 | $3.66 10-K · filed 2021-02-18 |
| 2019-12-31 | $0.66 10-K · filed 2020-03-02 |
| 2018-12-31 | $3.69 10-K · filed 2019-03-01 |
| 2017-12-31 | $3.01 8-K · filed 2019-01-29 |
| 2016-12-31 | $4.67 10-K · filed 2017-03-01 |
| 2015-12-31 | $3.93 10-K · filed 2016-02-29 |
| 2014-12-31 | $3.45 10-K · filed 2015-02-27 |
| 2013-12-31 | $2.46 10-K · filed 2014-03-03 |
| 2012-12-31 | $2.19 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |